Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

OPERA: French Observational Study on Patients Implanted With a Guidant PRIZM or Vitality Defibrillator

This study has been completed.
Information provided by (Responsible Party):
Boston Scientific Corporation Identifier:
First received: September 12, 2005
Last updated: February 17, 2017
Last verified: February 2017
This study evaluates the date of the first appropriate and/or inappropriate therapy in patients implanted with a Guidant PRIZM or VITALITY defibrillator and is evaluating eventual predictive risk factors for appropriate/inappropriate therapies as well as the influence of the programmed parameters on these therapies.

Condition Intervention
Ventricular Tachycardia
Ventricular Fibrillation
Device: Prizm, Vitality, Renewal

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: OPERA: French Observational Study on Patients Implanted With a Guidant PRIZM or Vitality Defibrillator

Resource links provided by NLM:

Further study details as provided by Boston Scientific Corporation:

Primary Outcome Measures:
  • Time to first appropriate therapy [ Time Frame: 2 year-follow-up ]
  • Time to first inappropriate therapy [ Time Frame: 2 year-follow-up ]

Secondary Outcome Measures:
  • Influence of cardiopathy, EF, NYHA Class, Type of ventricular arrhythmia (MVT, PVT, VF), History of atrial and ventricular arrhythmias, medical treatment (betablockers and/or Amiodarone). [ Time Frame: 2 year-follow-up ]
  • Type of treatment ATP/shock [ Time Frame: 2 year-follow-up ]

Enrollment: 636
Study Start Date: May 2002
Study Completion Date: August 2007
Primary Completion Date: August 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Device: Prizm, Vitality, Renewal
    Follow-up during 2 years
    Other Name: ICD and CRT-D
Detailed Description:
The registry measured the times to, and studied the determinants of, first appropriate (FAT) and inappropriate (FIT) therapy delivered by single, dual and triple chamber (CRT-D) ICD implanted for primary and secondary prevention indications.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients with a conventional indication of ICD or CRT-D

Inclusion Criteria:

  • Indication for an ICD according to current guidelines, incl. prophylactic indication

Exclusion Criteria:

  • pregnant or at birth bearing age without contraception, participation in another clinical trial, short life expectancy, geographically unstable for a follow-up at the investigational center
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00180375

CHG Aix en Provence
Aix en Provence, France, 13616
CHG Albi
Albi, France, 81000
CH Amiens
Amiens, France, 80054
CHU Angers
Angers, France, 49033
Hopital Angouleme
Angouleme, France, 16470
CH Avignon
Avignon, France, 84902
CH Besancon
Besancon, France, 25030
CHU Hopital la Cavale Blanche
Brest, France, 29609
Hopital Cote de Nacre
Caen, France, 14033
CHG Chateauroux
Chateauroux, France, 36019
Hopital Antoine Beclere
Clamart, France, 92140
CHU Clermont Ferrand
Clermont Ferrand, France, 63003
CHU Michalon
Grenoble, France, 38043
CH La Roche sur Yon
La Roche sur Yon, France, 85025
CHU Dupuytren
Limoges, France, 87042
Hopital Neuro-cardiologique
Lyon, France, 69394
CH St. Joseph
Marseille, France, 13008
GH La Timone
Marseille, France, 13385
Hopital Nord
Marseille, France, 13915
CHG Martigues
Martigues, France, 13696
Hôpital Princesse de Grâce
Monaco, France, 98000
CHU Montpellier
Montpellier, France, 34295
CHU Nantes
Nantes, France, 34295
CHU Nice
Nice, France, 6002
CHU D'Orleans
Orleans, France, 45000
Pau, France, 64046
CHRU Robert Debré
Reims, France, 51092
CHU Pontchaillou
Rennes, France, 35033
CHU Rouen
Rouen, France, 76031
CMC Arnaud Tzanck
St. Laurent du Var, France, 6700
CHU Toulon
Toulon, France, 83056
CHU Rangueil
Toulouse, France, 31403
CHU Tours
Tours, France, 37044
Sponsors and Collaborators
Boston Scientific Corporation
Principal Investigator: Antoine LEENHARD, MD Hôpital Lariboisière, Paris
  More Information

Responsible Party: Boston Scientific Corporation Identifier: NCT00180375     History of Changes
Other Study ID Numbers: OPERA Registry
Study First Received: September 12, 2005
Last Updated: February 17, 2017
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Tachycardia, Ventricular
Ventricular Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes processed this record on April 25, 2017